Qlaris Bio is developing therapeutics to treat serious and debilitating ophthalmic diseases. Patients with certain ophthalmic diseases suffer a progressive and permanent loss of vision over time, with glaucoma remaining a leading cause of preventable blindness worldwide. To address glaucoma, Qlaris is investigating new mechanisms of action driving glaucoma that can be targeted using therapies with a sustained duration of action to reduce the burden of eyedrops and to work independently from intraocular pressure-lowering drugs so that the optic nerve can be better protected. Qlaris’ lead program, QLS-111, has a unique vasodilatory mechanism of action and is now being progressed into clinical trials.

Qlaris Bio

Founded: 2019
Location: Dedham, MA
Employee range: 1 - 10
Clinical stage: Clin1
Therapy area: Open angle glaucoma, ocular hypertension
Drug types: OPH, PED, RAR
Lead product: QLS-111
Funding: &lt;10M

Drug notes:

About:

Jobs: